BIO Professional Development
Through a curated network of education alliance partners, BIO offers industry professionals executive training and development resources for accelerating career growth
Immunology Primer 101
Immunology Primer 101 reveals the intricate workings of the human immune system, highlighting the difference between non-specific and specific immunity. It uncovers the mysteries of how our bodies combat cancer and infections, exploring the roles of immune cells and tissues acting in our defense. This class showcases the remarkable link between our natural defenses and headline grabbing therapeutic antibodies developed by the biopharmaceutical industry. These therapies have revolutionized disease treatment for a host of diseases. Immunology Primer 101 is the perfect starting point for those new to understanding immunotherapies. Don't miss the chance to join us!
Takeaways
- Highlight the differences between non-specific and specific immunity.
- Name the cells and the tissues of the immune system.
- Compare how the immune system distinguishes between self and non-self when fighting disease.
- Summarize the general steps of the non-specific immune system to combat disease.
- Discuss the relationship between the naturally occurring immune system and the immuneinspired therapies created by the biopharma industry.
Certificate Requirements
Complete the course quiz with a passing score of 75% or higher
Gain a comprehensive understanding of DNA, proteins, and cells, explaining how they are manipulated to create innovative therapies and diagnostic tools.
Discover biosimilar science, manufacturing, & regulations. Learn about protein structure & disease mitigation.
Dive into antibodies' versatile role in research & clinic. Explore monoclonals, diagnostics, & more. Enhance fluency in antibody science.
Dive deeper into immune systems: nonspecific & specific. Learn disease origins & immune responses for comprehensive understanding.
Explore foundational science of genetic modification -- the impetus for the creation of the biotechnology industry in the 1980s.